Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pharmaceutical Affairs Law Amendment Passes Diet
August 5, 2002
- Prulifloxacin Recommended for Approval
August 5, 2002
- Pharmaco-business Innovation Chair to Be Established at Univ. of Tokyo
August 5, 2002
- Views of the JPMA President Regarding the Amendment of the Pharmaceutical Affairs Law
August 5, 2002
- Dear-Doctor Letter Issued for Ticlopidine
August 5, 2002
- Risk Management, Cost-effectiveness Analysis Stressed: CMIC Seminar
August 5, 2002
- Council Insists on Entry of Private Corporations into Medical Facilities
August 5, 2002
- Serious ADRs Reported for 3 Products Including Edaravone
August 5, 2002
- Novartis to Offer Research Grants for Cancer, Diabetes
August 5, 2002
- Japan, EU to Start Drug GMP Mutual Recognition around July 2003
August 5, 2002
- REGULATORY NEWS IN BRIEF
August 5, 2002
- OTS NEWS IN BRIEF
August 5, 2002
- Korosho to Strictly Crack Down on Suspicious Health Foods
August 5, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 5, 2002
- Olympus: New Version of EndoALPHA
August 5, 2002
- Eisai to Promote Pfizer's Cerebyx in US
August 5, 2002
- Olympus ProMarketing: Periodontal Disease Prevention Tool PerioMicro
August 5, 2002
- Fujisawa Ties Up with MerLion of Singapore for Enzyme Research
August 5, 2002
- Hitachi Medical to Gear Up New Business, Overseas Marketing
August 5, 2002
- Wholesalers Must Finish Price Negotiations by Mid-year Settlement of Accounts: Mr Matsutani
August 5, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…